EQ101

News alerts, weekly reports and conference planners

Company:

Equillium

Drug class:

IL-15R antagonist, IL-2R antagonist, IL-9R antagonist

Related drugs:

‹

›

5ms

Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata (clinicaltrials.gov)

P2, N=30, Active, not recruiting, Equillium | Recruiting --> Active, not recruiting | Trial completion date: Nov 2023 --> Apr 2024 | Trial primary completion date: Oct 2023 --> Mar 2024

5 months ago

Enrollment closed • Trial completion date • Trial primary completion date

EQ101

almost3years

A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL (clinicaltrials.gov)

P1/2, N=50, Completed, Bioniz Therapeutics | Recruiting --> Completed | N=24 --> 50 | Trial completion date: Sep 2019 --> Jun 2020 | Trial primary completion date: Aug 2019 --> Jun 2020

almost 3 years ago

Clinical • Trial completion • Enrollment change • Trial completion date • Trial primary completion date

CD8 (cluster of differentiation 8)

EQ101

over3years

[VIRTUAL] Co-Inhibition of IL-2, IL-9 and IL-15 By the Novel Immunomodulator, Bnz-1, Provides Clinical Efficacy in Patients with Refractory Cutaneous T Cell Lymphoma in a Phase 1/2 Clinical Trial (ASH 2020)

BNZ-1, an IL-2, IL-9, and IL-15 inhibitor, may provide a novel treatment option for CTCL patients who relapsed or were refractory with conventional therapies with a favorable toxicity profile. The multifaceted approach of BNZ-1 leads to direct inhibition of malignant cells, activation of tumor immunity, and suppression of inflammation. Since BNZ-1 showed safety and efficacy in challenging rCTCL patient population, its further development in a phase 3 trial is planned.

over 3 years ago

Clinical • P1/2 data

IL2 (Interleukin 2)

EQ101